Ally Dering Anderson

Dr. Ally Dering Anderson

Department of Pharmacy Practice & Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
PDF file
PGPaul Gubbins
Paul Gubbins
MKMichael E. Klepser
Michael E. Klepser
AAAlly Dering Anderson
Ally Dering Anderson
KBKarri A. Bauer
Karri A. Bauer
KDKristin M. Darin
Kristin M. Darin
KSKimberly Scarsi
Kimberly Scarsi

1 January 2016 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
MKMichael E. Klepser
Michael E. Klepser
DKDonald G. Klepser
Donald G. Klepser
AAAlly Dering Anderson
Ally Dering Anderson
JMJacqueline A. Morse
Jacqueline A. Morse
JSJaclyn K. Smith
Jaclyn K. Smith
SKStephanie A. Klepser
Stephanie A. Klepser

1 May 2016 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
DKDonald G. Klepser
Donald G. Klepser
MKMichael E. Klepser
Michael E. Klepser
AAAlly Dering Anderson
Ally Dering Anderson
JMJacqueline A. Morse
Jacqueline A. Morse
JSJaclyn K. Smith
Jaclyn K. Smith
SKStephanie A. Klepser
Stephanie A. Klepser

1 April 2018 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
DKDonald Klepser
Donald Klepser
MKMichael E. Klepser
Michael E. Klepser
JSJaclyn K. Smith
Jaclyn K. Smith
AAAlly Dering Anderson
Ally Dering Anderson
MNMaggie Nelson
Maggie Nelson
LPLauren E. Pohren
Lauren E. Pohren

1 January 2015 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
TATolu P. Akinwale
Tolu P. Akinwale
AAAlex J. Adams
Alex J. Adams
AAAlly Dering Anderson
Ally Dering Anderson
MKMichael E. Klepser
Michael E. Klepser

1 July 2015 in Journal of Managed Care & Specialty Pharmacy
Verified
Journal Article
Closed access
DKDonald Klepser
Donald Klepser
CCCarolyn E. Corn
Carolyn E. Corn
MSMichael Schmidt
Michael Schmidt
AAAlly Dering Anderson
Ally Dering Anderson
MKMichael E. Klepser
Michael E. Klepser
BACKGROUND: Each year, 6%-20% of U.S. residents are infected by influenza, and more than 200,000 people are hospitalized due to complications related to influenza. In 2003, it was estimated that the direct medical costs for the treatment of influenza were $10.4 billion in the United States. OBJECTIVES: To (a) assess the current practice associated with the diagnosis and treatment of influenza-like illnesses (ILIs) in inpatient, ambulatory/outpatient, and emergency room settings and (b) evaluate how the use of rapid influenza diagnostic tests (RIDTs) impacts patient health care utilization and cost in these clinical settings. METHODS: For this retrospective cohort study, patients with an influenza-related health care encounter were identified using claims data from a midwestern commercial health insurance plan. In order to select the claims relevant to this study, the corresponding influenza ICD-9-CM codes, GPI codes, and CPT codes for the diagnosis, prescriptions, and procedures were identified and used to detect ILI claims. For the cost analysis of these data, the allowed amount in the billing claims was utilized. Using these data, the median cost, mean cost, minimum cost, and maximum cost were determined for each episode of care. The median costs were compared, and Wilcoxon two-sample tests and Kruskal-Wallis tests with a P value of 0.05 were used as the level of significance. RESULTS: Over 32% of the influenza-like illness episodes identified in this study involved empiric antiviral therapy as either treatment (15%) or prophylaxis (17.1%) without an accompanying medical visit. Of patient episodes with a medical visit, patients with an RIDT for influenza received antiviral treatment in 27.5% of the episodes compared with 55% of the episodes for patients with no RIDT. Episodes with a medical visit and an RIDT had statistically significant (P less than 0.001) lower median 30-day influenza-related health care costs ($62.46) than episodes with a medical visit but no RIDT ($192.83), as well as with empiric therapy but no accompanying medical visit ($105.64). CONCLUSIONS: The results of this analysis for ILI claims over a 2-year period suggest that utilization of RIDTs for influenza may reduce overall influenza-related health care costs and improve proper utilization of anti- influenza medications.